Conavi Medical launches OCTIV™ in the U.S. with first commercial placement and clinical cases
Summary
- Conavi Medical Corp. launched its OCTIV™ coronary imaging system in the U.S., combining intravascular ultrasound (IVUS) & optical coherence tomography (OCT) into a single catheter.
- The first U.S. commercial placement & clinical cases were completed on November 2, 2026, marking the system's entry into clinical use.
- OCTIV provides inherently co-registered, side-by-side imaging of the same artery segment, allowing physicians to access both depth & high-resolution detail simultaneously.
- The launch aligns with stronger guideline support, including the 2025 U.S. acute coronary syndromes guideline which gives IVUS or OCT a Class 1, Level A recommendation for stent implantation.
- A 2024 meta-analysis indicates intravascular imaging-guided procedures can reduce cardiac death risk by 45% compared to angiography guidance alone.
- Conavi showcased OCTIV at TCT 2026 in San Diego & is now focused on supporting clinical use at its first site while advancing placements at additional U.S. institutions.
- The company raised $10 million dedicated to the U.S. launch & limited market release to collect new data & case stories.
- Conavi's hybrid imaging system is FDA-cleared & represents the first technology to co-register & co-align IVUS & OCT beams for simultaneous hybrid imaging.
Tom Looby, President and CEO, and Amandeep Thind, CTO, of Conavi Medical Corp., discuss the U.S. launch of OCTIV™, the Toronto-based company’s coronary imaging system that puts two complementary imaging technologies into a single catheter.